The trial will initially involve healthy obese people receiving single and multiple escalating doses of the therapy.

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Adding zilebesiran to a thiazide diuretic or calcium channel blocker may lead to further blood pressure reduction in patients with uncontrolled hypertension. Zilebesiran added to hypertension ...

PASADENA, CA, USA I June 02, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a ...

A startup seeking to replace animal testing with a sophisticated high-tech platform has raised $40 million to develop ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

In summary, zilebesiran shows great promise as a long-acting treatment for high blood pressure. If future trials confirm its ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that ...